William Blair analyst Andrew Brackmann has reiterated their neutral stance on CDNA stock, giving a Hold rating on November 1.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Brackmann has given his Hold rating due to a combination of factors impacting CareDx’s financial outlook. The company reported mixed results in its third-quarter update, with revenue and volumes falling slightly short of expectations, primarily due to lower-than-anticipated kidney transplant volumes and complexities related to prior-period collections. However, there are promising signs from CareDx’s revenue cycle management initiatives, which are beginning to show success and offer potential for future revenue growth.
Despite these positive developments, there are still uncertainties, particularly regarding the draft LCD, which remains a significant concern and could affect the company’s financial model. Clarity on this issue is not expected until early 2026, making it challenging to justify an upgrade in the stock rating at this time. While there are growth drivers in place, such as the integration with Epic Aura, the lack of immediate clarity on regulatory matters leads to the decision to maintain a Hold rating until more information becomes available.
Brackmann covers the Healthcare sector, focusing on stocks such as Exact Sciences, Veracyte, and Hologic. According to TipRanks, Brackmann has an average return of 32.3% and a 68.09% success rate on recommended stocks.
In another report released on November 1, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $15.50 price target.